March 12 | March 13

1:00-6:30 / Registration

2:30-4:15 / Concurrent Session I:  Follow the Diabetes Dollar—Federal Priorities in Preventing and Treating Diabetes

Eighteen federal government agencies have diabetes-related responsibilities, including funding for basic research, prevention programs, approval of new treatments, and paying for healthcare services in Medicare, Medicaid, and other federal programs.  Learn how Congress and federal agencies, including CDC, NIH, FDA, CMS, the VA, and Indian Health Service make decisions about how federal dollars flow to diabetes programs.

2:30-4:15 / Concurrent Session II:  Payment for Innovation—Reimbursement for Diabetes Therapies in the United States

Manufacturers of drugs and devices, payers, and the federal government are engaged in ongoing dialogue about how best to value and pay for new technologies, cognitive services, and disease management programs for diabetes patients. Hear clinical and reimbursement experts from across the public and private sectors examine these issues in depth.

4:15-4:30 / Break

4:30-5:00 / Welcoming Remarks: Diabetes at a Crossroads

Over 20 million Americans have diabetes, creating both opportunities and challenges for leaders in healthcare and public policy.  Learn about marketplace innovations in treatment, mounting tensions among manufacturers, payers, and providers about evidence and payments, and directions in policymaking that will influence future commercial investments and clinical care. 

5:00-5:45 / Plenary Session

5:45-6:30 / Networking Reception

6:30-8:30 / Dinner and Keynote Address

Back to top

March 12 | March 13

7:30-4:00 / Registration

7:30-8:00 / Continental Breakfast

8:00-9:00 / Next Generation Treatments: Research and Markets

Diabetes treatment is evolving rapidly.  Drug manufacturers are developing new products that promise more convenient dosing and less invasive delivery, while devices that continuously monitor glucose levels and deliver insulin are becoming smarter and smaller.  New discoveries in diabetes research will lead to personalized medicines in the future.  Wall Street, product reimbursement, and pharmacy experts will discuss the latest innovations in the diabetes pipeline, how Wall Street views the diabetes market, and the influence of payers over investments in new product development. 

9:00-10:00 / Eliminating Disparities: Prevention and Screening Initiatives in Diabetes

Trends in diabetes epidemiology and obesity will require focusing resources on prevention, particularly in an increasingly diverse population of children and young adults.  Screening can be a powerful tool in managing the surge of diabetes in the United States, yet experts argue that detection programs are not fully utilized.  A panel of prevention, public health, and patient advocacy experts will discuss initiatives currently underway to screen patients for diabetes, the impact of health disparities on use of diabetes prevention and screening services, and opportunities to maximize the potential of diabetes prevention and screening.

10:00-10:30 / The Impact of Medicare Part D on Beneficiaries with Type 2 Diabetes: Drug Utilization and Out-of-Pocket Cost

10:30-10:45 / Break

10:45-11:45 / Navigating the Maze: Health Insurance Issues for Patients with Diabetes

Patients with diabetes rely on a wide continuum of healthcare services, ranging from screening and early detection to treatment and self-management to preventing complications; insurance is a critical link to successful disease management.  Experts will review how commercial payers, Medicare, Medicaid, and safety-net programs cover services used by people with diabetes, how insurance coverage and health disparities affect patients with diabetes, and policy solutions that could expand coverage to a broader range of treatments and services.     

11:45-12:45 / Working Together: Coordinating Diabetes Care Across the Healthcare System

Improving coordination of care and adherence to evidence-based treatment guidelines may improve quality of care and save money.  Measures of the quality of diabetes care are widely collected, but tension is mounting as providers advocate for higher payments for cognitive services while payers contemplate payment reforms such as pay-for-performance and global management fees.  Hear from experts who are experimenting with new approaches as they discuss their vision for the future of diabetes care.

12:45-2:00 / Lunch and Keynote Address

2:00-2:15 / Break

2:15-2:45 / Focusing Federal Efforts: A Review of Health-Related Offices, Commissions, Panels, and Conferences

2:45-3:30 / Future Congressional Action: The View from Washington 

Hear directly from the Hill on how Congress views diabetes and its connection into broader health system reform.  Leading policymaking staff will examine policy proposals being considered in the Congress to improve diabetes care, the challenges of crafting effective policy in a budget-neutral environment, and areas of future congressional focus that may impact the diabetes community. 

3:30-4:30 / Going Digital: The Role of Technology in Diabetes Self-Management

Innovations in information technology are enabling patients to self-manage their care more easily from home.  Experts in diabetes education and patient self-management will examine the latest research findings and their impact on patient health, while information technology experts will discuss how new technologies are transforming the field.

4:30-4:45 / Closing Remarks

Back to top